Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients

American Journal of Transplantation

Volumn 7, Issue 1, 2007, Pages 249-255

  Kreijveld, E ^a   Koenen, H J P M ^a   Klasen, I S ^a   Hilbrands, L B ^a   Joosten, I ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CD4+CD25 + regulatory T cell; Daclizumab; Human kidney transplantation; IL 2; IL 2R

Indexed keywords

AZATHIOPRINE; DACLIZUMAB; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; BLOOD; CD4+ CD25+ T LYMPHOCYTE; CIRCULATION; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MALE; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CD4 LYMPHOCYTE COUNT; FEMALE; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY TRANSPLANTATION; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 33845675770     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01604.x     Document Type: Article

References (18)

1. Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005; 56(1): 23-46.
2. Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338(3): 161-165.
3. Bestard O, Cruzado JM, Grinyo JM. Corticosteroid-sparing strategies in renal transplantation: are we still balancing rejection risk with improved tolerability? Drugs 2006; 66(4): 403-414.
4. Lowenthal JW, Zubler RH, Nabholz M, MacDonald HR. Similarities between interleukin-2 receptor number and affinity on activated B and T lymphocytes. Nature 1985; 315(6021): 669-672.
5. Malek TR, Yu A, Vincek V, Scibelli P, Kong L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 2002; 17(2): 167-178.
6. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188(2): 287-296.
7. Shevach EM. CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2002; 2(6): 389-400.
8. Koenen HJ, Joosten I. Blockade of CD86 and CD40 induces alloantigen-specific immunoregulatory T cells that remain anergic even after reversal of hyporesponsiveness. Blood 2000; 95(10): 3153-3161.
9. Bayer AL, Yu A, Adeegbe D, Malek TR. Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period. J Exp Med 2005; 201(5): 769-777.
10. D'Cruz LM, Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 2005; 6(11): 1152-1159.
11. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6(11): 1142-1151.
12. Chai JG, Xue SA, Coe D et al. Regulatory T cells, derived from naive CD4+. Transplantation 2005; 79(10): 1310-1316.
13. Kingsley CI, Karim M, Bushell AR, Wood KJ. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002; 168(3): 1080-1086.
14. ter Meulen CG, Jacobs CW, Wetzels JF, Klasen IS, Hilbrands LB, Hoitsma AJ. The fractional excretion of soluble interleukin-2 receptor-alpha is an excellent predictor of the interleukin-2 receptor-alpha status after treatment with daclizumab. Transplantation 2004; 77(2): 281-286.
15. Koenen HJ, Fasse E, Joosten I. CD27/CFSE-based ex vivo selection of highly suppressive alloantigen-specific human regulatory T cells. J Immunol 2005; 174(12): 7573-7583.
16. van de LP, Tysma OM, Medema JP, Hale G, Waldmann H, Roelen DL et al. Mechanisms of antibody immunotherapy on clonal islet reactive T cells. Hum Immunol 2006; 67(4-5): 264-273.
17. Coenen JJ, Koenen HJ, van RE, Hilbrands LB, Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006; 107(3): 1018-1023.
18. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105(12): 4743-8.